10 Biggest Price Target Changes For Thursday
Benzinga2022-01-20
- Piper Sandler cut Advanced Micro Devices, Inc. price target from $140 to $130. AMD shares fell 1.3% to $126.55 in pre-market trading.
- BMO Capital boosted Vertex Pharmaceuticals Incorporated price target from $202 to $274. Vertex Pharmaceuticals shares rose 0.6% to $232.16 in pre-market trading.
- Keybanc cut Allbirds, Inc. price target from $28 to $24. Allbirds shares rose 0.4% to $13.89 in pre-market trading.
- Raymond James raised the price target for Tenet Healthcare Corporation from $105 to $120. Tenet Healthcare shares rose 2.1% to $78.75 in pre-market trading.
- Keefe, Bruyette & Woods reduced the price target on U.S. Bancorp from $73 to $64. U.S. Bancorp shares rose 0.4% to $57.60 in pre-market trading.
- Goldman Sachs lowered the price target for Silvergate Capital Corporation from $190 to $166. Silvergate Capital shares rose 1.9% to $111.35 in pre-market trading.
- Wells Fargo cut Ashland Global Holdings Inc. price target from $120 to $110. Ashland Global shares fell 0.9% to $99.00 in pre-market trading.
- Piper Sandler lowered the price target on NXP Semiconductors N.V. from $235 to $210. NXP Semiconductors shares fell 1.5% to $207.78 in pre-market trading.
- HC Wainwright & Co. cut Kintara Therapeutics, Inc. price target from $6 to $3. Kintara Therapeutics shares rose 2.9% to $0.4403 in pre-market trading.
- Keybanc lowered the price target on Lyft, Inc. from $72 to $65. Lyft shares fell 0.3% to $36.81 in pre-market trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
